1 / 58

Nosocomial Infections

Nosocomial Infections. David M. Parenti, M.D. Definitions. sterilization : use of physical procedures or chemical agents to destroy all microbes, including spores, viruses, fungi disinfection : use of physical procedures or chemical agents to destroy most microbes

irisj
Télécharger la présentation

Nosocomial Infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nosocomial Infections David M. Parenti, M.D.

  2. Definitions • sterilization: use of physical procedures or chemical agents to destroy all microbes, including spores, viruses, fungi • disinfection: use of physical procedures or chemical agents to destroy most microbes • high, intermediate, low level • antisepsis: use of chemical agents on skin or other tissue to inhibit or kill microbes

  3. Nosocomial Infections • Infection acquired in the hospital: > 48 hours after admission • $5 billion annually: increased hospital length of stay, antibiotics, morbidity and mortality • related to severity of underlying disease, immunosuppression, invasive medical interventions • frequently caused by antibiotic-resistant organisms: MRSA, VRE, resistant Gram-negative bacilli, Candida

  4. Sites of Nosocomial Infections Pneum SSI 11% 20% UTI Other 22% 36% BSI 11% Klevens. Pub Health Rep 2007;122:160

  5. Nosocomial InfectionTypes of Transmission • airborne • tuberculosis, varicella, Aspergillus • contact • S. aureus, enterococci, Gram-negative bacilli • common vehicle • food contamination • Salmonella, hepatitis A

  6. Patient 1 • A 67 yo female with poorly controlled hypertension was admitted because of a right-sided stroke. She had confusion, limitation of mobility of her left leg, and urinary incontinence. A urinary (Foley) catheter was placed and she was evaluated for rehabilitation. • 4 days later she developed a temp to 103º F and blood pressure of 90/60 and was transferred to the ICU. Blood and urine cultures grew resistant Klebsiella.

  7. Nosocomial UTI • Up to 25% of hospitalized patients are catheterized at some time during their hospital stay. • 15% colonized (bacteruria) • 5-10% per day of catheterization • 50% after 14 days • Gram-negative bacilli, VRE, Candida • frequent antimicrobial resistance

  8. Antibiotic-ResistantGram-Negative Bacilli • increasingly a problem in the ICU: UTI, pneumonia • selective pressure from high-level antibiotic usage in hospital and community • E. coli, Klebsiella, Enterobacter, Pseudomonas, Serratia, Acinetobacter • resistance to extended spectrum penicillins, cephalosporins, aminoglycosides, quinolones • colonization at multiple body sites: GI, skin, pharynx

  9. Nosocomial UTI Pathogenesis • external • most common • colonization of urethral meatus • movement of bacteria along fluid layer on external catheter surface • internal • colonization of urine in bag, ascend through catheter lumen

  10. Nosocomial UTI Prevention • *avoid catheterization • minimize duration of catheterization • intermittent (“in and out”) catheterization • aseptic insertion technique • closed system • dependent drainage • silver-coated catheters

  11. Patient 2 • A 45 yo male is admitted for community-acquired pneumonia. He has a long history of iv drug use, but has not used in several years. The intern has difficulty starting a peripheral iv so places a femoral venous catheter. His cough and fever begin to improve. • On hospital day 3 he has fever, chills and a WBC of 18,000. Blood cultures are positive for vancomycin-resistant Enterococcus.

  12. Vascular Device-Associated Bacteremia • major cause of morbidity and mortality in hospitalized patients • 150 million intravascular devices are purchased by hospitals yearly • estimated 50,000-100,000 intravascular device- related bacteremias in U.S./year • non-cuffed central venous catheters account for 90% of vascular catheter-related bacteremias

  13. CVC-Associated BacteremiasGWUH 2009 • Staphylococcusaureus, MRSA, S. epidermidis • Enterococcusfaecalis, VRE • Streptococcusagalactiae (group B strep) • Acinetobacter, Klebsiellapneumoniae, Enterobactercloacae • Candidaalbicans, C.parapsilosis

  14. Vascular Device-Associated Bacteremia: Pathogenesis • initial step is colonization of the insertion or access hub • biofilm formation allows attachment of bacteria • development of bacteremia

  15. IV Catheter Biofilm 24 hours after Insertion

  16. Coagulase Negative StaphylococciSlime-producing, Catheter Surface

  17. Vascular Catheter InfectionsRisk Factors • type of catheter: plastic > steel • multiple > single lumen • location of catheter • central > peripheral • internal jugular, femoral > subclavian • duration of placement: > 72 hours • emergent placement > elective • skill of venipuncturist: others > i.v. team

  18. Vascular Catheter InfectionsClinical Clues • local inflammation or phlebitis at catheter insertion site • bacteremia caused by associated organisms: MRSA, CNS, VRE, Candida above waist 38% hand or arm 29% inguinal area 86% Bonten MJM . Lancet 1996; 348:1615

  19. Vascular Catheter InfectionsDiagnosis • Maki rollplate technique • catheter tip or intracutaneous segment is rolled on agar plate • colonies are counted • > 15 colonies correlates with colonization and potential source of bacteremia Maki DG. NEJM 1977;296:1305

  20. Semipermanent Tunneled Catheters (Groshong, Hickman, Mediport) • long term i.v. therapy • much lower rate of infection • dacron cuff incites inflammatory response, fibrosis at insertion site • prevents bacteria from migrating along external catheter surface • locations of infection: exit site, tunnel, tip • tunnel infection always requires catheter removal • septic thrombophlebitis/pulmonary emboli

  21. Groshong catheter

  22. CVC-Associated BacteremiaPrevention (Bundles) • *minimize duration of catheterization • use single vs multiple lumen catheters • site placement • meticulous insertion technique • drapes, gown/gloves/mask • antibiotic impregnated catheters • impregnated dressing (Biopatch) • outbreak/cluster control

  23. Chlorhexidine/Silver Sulfadiazine-Coated CVCs • 158 hospitalized patients with 403 triple-lumen, polyurethane venous catheters • chlorhexidine/silver sulfadiazine-coated vs uncoated catheters-external surface uncoatedcoatedp • colonization 24.1% 13.5% < 0.005 • bacteremia 4.7% 1% < 0.03 Maki DG; Ann Intern Med 1997;127:257

  24. VRE RFLP GWUH 2004 * * * * * * * *

  25. Patient 3 • A 52 yo male is admitted with a severe headache and is found to have a subarachnoid hemorrhage from a ruptured aneurysm. The neurosurgeons evacuate the hematoma and clip his aneurysm. Post-op he remains on a ventilator. • On hospital day 5 he spikes a fever to 102º F and is noted to have copious secretions from his endotracheal tube. Increasing amounts of inspired O2 are required. Blood and sputum cultures grow highly resistant Enterobactercloacae.

  26. Nosocomial Pneumonia • 300,000 cases/year in U.S. • 10-15% of nosocomial infections • leading cause of death from nosocomial infection • crude mortality 35-50% • ventilator-associated pneumonias occur 48-72 h post endotracheal intubation • organisms may originate from endogenous flora, other patients, visitors, or environmental sources

  27. Ventilator Associated Pneumonia GWUH 2009 • Staphylococcusaureus, MRSA • Proteusmirabilis, Serratiamarcescens, Pseudomonasaeruginosa, Stenotrophomonasmaltophilia

  28. Nosocomial Pneumonia EpisodesMortality Klebsiella, 30% 40% Enterobacter S. aureus 27% 33% P. aeruginosa 15% 72% S. pneumoniae 12% 43% E. coli 10% 31% anaerobes 2% 0% Bryan CS. Am Rev Resp Dis 1984;129:668-671

  29. Gram-Negative Bacilli ColonizationRisk Factors • severity of underlying illness • duration of hospitalization • prior or concurrent use of antibiotics • advanced age • intubation • major surgery • achlorhydria ?

  30. Ventilator-Associated PneumoniaPrevention • *limit duration of ventilation • handwashing/gloves • closed ventilator circuits • semi-recumbent positioning • avoid large gastric volumes • avoid prolonged nasal intubation • prevent sinusitis • ? maintain gastric acidity

  31. Patient 4 • A 73 yo male is admitted with chest pain and severe coronary artery disease. He has emergent 3-vessel coronary artery bypass grafting. He recovers fairly well from the surgery but on post-op day 10 develops fever and purulent drainage from the inferior aspect of the wound. • He returns to the operating room for extensive debridement of sternal osteomyelitis. Cultures grow methicillin-resistant Staphylococcusaureus.

  32. Patient 4

  33. Surgical Site Infection (SSI) • usually introduction of skin organisms into the wound • S. aureus, Gram-negative bacilli • risk factors • underlying disease • skill of the operator • duration of operative procedure • may not become clinically apparent until after discharge • risk may be decreased by appropriately timed pre-operative antibiotics

  34. MRSA • 1960 methicillin-resistant S. aureus identified • MRSA 60% of S. aureus isolates at GW are MRSA (2007) • Community-acquired: recent increase in incidence • Hospital-acquired: > 48 h after admission • Healthcare-associated community-onset: • previous positive MRSA culture • history of hospitalization, surgery, dialysis or residence in long term care facility in the last year • indwelling catheter/percutanous device

  35. MRSA IsolatesPulse Field Gel Electrophoresis (PFGE)

  36. MRSAMechanism of Resistance • chromosomal mecA gene • *altered PBP 2´ or 2a in cell wall • low affinity for all ß-lactam antibiotics

  37. Hospital-acquired MRSA • BSI 76% • pneumonia 13% • osteomyelitis 6% • endocarditis 3% • cellulitis 4% • skin abscess/necrosis 1% • mortality 2.5% www.cdc.gov/abcs

  38. Hospital-acquired MRSA • Risk factors: • prolonged hospitalization • prolonged antimicrobial therapy • location in an intensive care unit • proximity to a known MRSA case • Persistent colonization up to 4 years: nares • Contamination of environmental surfaces • up to 30%: bed rails, table, BP cuff

  39. SSI Prevention • no shaving of operative site: clippers or no hair removal • hand hygiene; fastidious aseptic technique • surgical site antisepsis with chlorhexidine • prophylactic antibiotics • single dose 30-60 minutes prior to incision • second dose for prolonged surgeries • laminar air flow or HEPA filtration; limit traffic in the operating room • pre-operative screening for S. aureus

  40. Patient 5 • A 26 yo medical student draws blood from a patient for a classmate. He is in a hurry and sticks his thumb while recapping (?) the needle. The patient has been tested positive for HIV and hepatitis C. The student has received the hepatitis B immunization series.

  41. HCW Blood/Body Fluid ExposureRisk Factors • needlestick/sharp>>mucosal>>non-intact skin • inoculum: viral titer, volume of blood • needle type • hollow-bore needles > solid-bore • large bore > small bore • decreased risk with glove use

  42. GWU Health Care WorkersPercutaneous Exposures: 2007-09 • Occupation • Hospital staff 38-49%* • Residents 39-56%* • Students 6-11% • Location • ER 7-14% • ICU 7-21%* • OR 31-52%* • other floors 24-27%* • Pathology 3-8%

  43. Risk of Transmission following Percutaneous Exposure • HIV 0.3% • Hepatitis C 1.9% • HBeAg - < 6% • HBeAg + 30% • estimated US transmission for yr 2000* • 390 cases of HCV • 40 cases of HBV • 5 cases of HIV Henderson DK. Clin Microbiol Rev.2003;16:546 * Prüss-Üstün A. Am J Ind Med 2005;48:482

  44. HCW Blood/Body Fluid ExposureManagement • baseline serologies, including the patient if necessary • assessment of risk • HIV: antiretroviral therapy • hepatitis B: hepatitis B immune globulin and hepatitis B vaccine if non-immune • hepatitis C: close follow up

  45. HCW Blood/Body Fluid ExposurePrevention • SLOW DOWN • do not recap needles • dispose of sharps in the proper receptacle • use needleless systems whenever possible • heptitis B immunization

  46. Isolation • to protect both patients and personnel • StandardPrecautions • routinely consider all body fluids and moist surfaces as potentially infectious • airborne precautions • droplet precautions • contact precautions

  47. IsolationAirborne Precautions • transmission of pathogen via inhalation of droplet nuclei • tuberculosis, varicella, ? influenza • private room • negative pressure • > 10 air exchanges per hour • Staff: particulate respirators

More Related